Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.
- FY2026 net loss of $15.38 million
- XanaMIA Alzheimer's trial fully enrolled with topline results due November
- Open-label extension phase launched with 89% participant rollover
- Regulatory alignment achieved with FDA and EMA for streamlined approval
- $16.7 million cash on hand provides runway beyond trial results
Pivotal Alzheimer's Trial Nearing Crucial Readout
Actinogen Medical (ASX:ACW) is on the cusp of delivering critical topline data from its pivotal XanaMIA Phase 2b/3 trial evaluating Xanamem, its oral 11β-HSD1 inhibitor targeting brain cortisol dysregulation in Alzheimer's disease. The trial, fully enrolled with 247 patients across Australia and the US, is set to report results in November 2026. Independent Data Monitoring Committee (DMC) reviews have been consistently positive, including a confidential non-futility efficacy analysis in January, supporting continuation without amendment.
The trial's primary endpoint is the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB), an internationally recognized measure of cognitive and functional decline. An open-label extension (OLE) phase commenced in March 2026, with 89% of participants rolling over, now totaling 108 patients on active treatment. This extension will provide longer-term safety and efficacy data, potentially informing future regulatory submissions.
Regulatory Progress and Planned Next Steps
Actinogen has secured common understandings with both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the regulatory pathway for Xanamem's approval in Alzheimer's disease. These include agreement on the suitability of manufacturing materials, safety database requirements, and the design of one additional pivotal Phase 3 trial, planned to commence mid-2027 with a broader patient population across multiple countries.
Should the XanaMIA trial deliver positive results, Actinogen may explore accelerated approval pathways with regulators, using the second pivotal trial as a post-approval commitment. This regulatory alignment provides external validation of Xanamem’s development strategy and supports ongoing commercial and partnering discussions.
Financial Position and Capital Management
For the fiscal year ended 30 June 2026, Actinogen recorded a net loss after tax of $15.38 million, a moderate increase from the prior year’s $14.73 million loss, largely driven by ramped-up research and development (R&D) expenses of $19 million as clinical activities peaked. Employment costs rose due to new hires supporting trial execution, while corporate and administration costs remained stable.
The company closed the year with $16.7 million in cash and equivalents, supplemented by an expected $10.8 million R&D tax rebate anticipated in Q2 FY2027. A successful $16.8 million capital raising in early 2026, combined with non-dilutive funding secured against future R&D tax incentives, has extended the cash runway through mid-2027, comfortably beyond the anticipated trial readout.
Strengthening Intellectual Property and Manufacturing
Actinogen continued to bolster its intellectual property portfolio with new patent filings covering Xanamem’s use in treating cognitive decline in healthy elderly populations and key manufacturing processes. The company received initial national acceptances in jurisdictions including Australia, Russia, China, and Chile. Notably, China enacted a six-year data exclusivity provision, potentially shielding Xanamem from generic competition post-approval.
On the manufacturing front, Actinogen completed production of additional commercial-grade 10 mg Xanamem tablets at Catalent in the US, supporting the OLE phase and future clinical trials. A pharmacokinetic study confirmed consistent therapeutic blood levels under fed and fasted conditions, endorsing dosing flexibility for real-world use.
Expanding Scientific and Commercial Foundations
Beyond Alzheimer's, Xanamem has shown promising antidepressant activity in a phase 2a trial of patients with treatment-resistant depression and baseline cognitive impairment. These results, published in the British Journal of Psychiatry, demonstrated clinically meaningful improvements in depression scores, reinforcing the cortisol control mechanism's therapeutic potential.
Actinogen has also invested in commercial readiness, establishing an Alzheimer’s Disease Clinical Advisory Committee of global experts and engaging key opinion leaders to shape market positioning. With interest from potential commercialization partners growing, the company is actively preparing for strategic partnerships to maximize Xanamem’s global value.
Governance and Leadership
The company’s Board and executive team, led by CEO Dr Steven Gourlay, have navigated the complex late-stage clinical development landscape with discipline, securing regulatory milestones and funding while expanding operational capabilities. The Board maintains a strong governance framework and oversight, with all directors fully engaged in steering Actinogen through this pivotal phase.
Remuneration disclosures reveal a balanced mix of fixed salary, short-term incentives tied to performance metrics, and long-term incentives via loan shares and options, aligning management interests with shareholder value creation.
Bottom Line?
With pivotal Alzheimer's trial results due imminently, Actinogen is positioned at a critical inflection point; the data will be decisive for its clinical and commercial trajectory.
Questions in the middle?
- Will the November XanaMIA topline data meet efficacy expectations to justify accelerated regulatory pathways?
- How will Actinogen navigate the competitive Alzheimer’s landscape if Xanamem gains approval alongside emerging anti-amyloid therapies?
- What strategic partnerships might Actinogen pursue post-trial to optimize global commercialisation and development?